FBRX – Forte Biosciences Inc
Forte Biosciences, Inc.FBRX
$11.32Name : Forte Biosciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $74,523,856.00
EPSttm : -9.51
Forte Biosciences, Inc.
$11.32
9.37%$0.97Float Short %
2.43
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.26
EPS Last/This Y
7.52
EPS This/Next Y
1.85
Price
11.11
Target Price
48.67
Analyst Recom
1
Performance Q
74.15
Relative Volume
0.38
Beta
2.85
Ticker: FBRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | FBRX | 6.45 | N/A | N/A | 0 |
| 2025-05-09 | FBRX | 6.38 | N/A | N/A | 0 |
| 2025-05-12 | FBRX | 6.35 | N/A | N/A | 0 |
| 2025-05-13 | FBRX | 6.8 | N/A | N/A | 0 |
| 2025-05-14 | FBRX | 8 | N/A | N/A | 0 |
| 2025-05-15 | FBRX | 7.83 | N/A | N/A | 0 |
| 2025-05-16 | FBRX | 7.81 | N/A | N/A | 0 |
| 2025-05-19 | FBRX | 7.65 | N/A | N/A | 0 |
| 2025-05-20 | FBRX | 7.61 | N/A | N/A | 0 |
| 2025-05-21 | FBRX | 7.07 | N/A | N/A | 0 |
| 2025-05-22 | FBRX | 7.56 | N/A | N/A | 0 |
| 2025-05-23 | FBRX | 8.09 | N/A | N/A | 0 |
| 2025-05-27 | FBRX | 11.65 | N/A | N/A | 0 |
| 2025-05-28 | FBRX | 9.66 | N/A | N/A | 0 |
| 2025-05-29 | FBRX | 8.98 | N/A | N/A | 0 |
| 2025-05-30 | FBRX | 8.68 | N/A | N/A | 0 |
| 2025-06-02 | FBRX | 8.93 | N/A | N/A | 0 |
| 2025-06-03 | FBRX | 9.58 | N/A | N/A | 0 |
| 2025-06-04 | FBRX | 10.05 | N/A | N/A | 0 |
| 2025-06-05 | FBRX | 10.37 | N/A | N/A | 0 |
| 2025-06-06 | FBRX | 11.45 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | FBRX | 6.60 | 76.3 | - | -3.60 |
| 2025-05-09 | FBRX | 6.38 | 76.3 | - | -3.60 |
| 2025-05-12 | FBRX | 6.28 | 76.3 | - | -3.60 |
| 2025-05-13 | FBRX | 6.80 | 76.3 | - | -3.60 |
| 2025-05-14 | FBRX | 8.22 | 76.3 | - | -3.60 |
| 2025-05-15 | FBRX | 7.95 | 76.3 | - | -3.60 |
| 2025-05-16 | FBRX | 7.96 | 76.3 | - | -3.60 |
| 2025-05-19 | FBRX | 7.50 | 76.3 | - | -3.60 |
| 2025-05-20 | FBRX | 7.77 | 83.6 | - | -3.60 |
| 2025-05-21 | FBRX | 7.20 | 83.6 | - | -3.60 |
| 2025-05-22 | FBRX | 7.53 | 83.6 | - | -3.60 |
| 2025-05-23 | FBRX | 7.92 | 83.6 | - | -3.60 |
| 2025-05-27 | FBRX | 11.53 | 80.9 | - | -4.93 |
| 2025-05-28 | FBRX | 9.20 | 80.9 | - | -4.93 |
| 2025-05-29 | FBRX | 8.25 | 80.9 | - | -4.93 |
| 2025-05-30 | FBRX | 8.50 | 80.9 | - | -4.93 |
| 2025-06-02 | FBRX | 8.79 | 80.9 | - | -4.93 |
| 2025-06-03 | FBRX | 9.55 | 80.9 | - | -4.93 |
| 2025-06-04 | FBRX | 9.98 | 80.9 | - | -4.93 |
| 2025-06-05 | FBRX | 10.35 | 80.9 | - | -4.93 |
| 2025-06-06 | FBRX | 11.11 | 80.9 | - | -4.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | FBRX | 1.82 | 4.46 | 1.97 |
| 2025-05-09 | FBRX | 1.82 | 4.46 | 1.97 |
| 2025-05-12 | FBRX | 1.82 | 4.46 | 2.06 |
| 2025-05-13 | FBRX | 1.82 | 4.46 | 2.06 |
| 2025-05-14 | FBRX | 1.82 | 4.46 | 2.06 |
| 2025-05-15 | FBRX | 1.82 | 4.46 | 2.06 |
| 2025-05-16 | FBRX | 1.82 | 4.46 | 2.06 |
| 2025-05-19 | FBRX | 1.82 | 184.81 | 2.05 |
| 2025-05-20 | FBRX | 1.83 | 184.81 | 2.05 |
| 2025-05-21 | FBRX | 1.83 | 184.81 | 2.05 |
| 2025-05-22 | FBRX | 1.83 | 184.81 | 2.05 |
| 2025-05-23 | FBRX | 0.00 | 184.81 | 2.05 |
| 2025-05-27 | FBRX | 0.00 | -8.98 | 2.05 |
| 2025-05-28 | FBRX | 0.00 | -8.98 | 2.43 |
| 2025-05-29 | FBRX | 0.00 | -8.98 | 2.43 |
| 2025-05-30 | FBRX | 0.00 | -8.98 | 2.43 |
| 2025-06-02 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-03 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-04 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-05 | FBRX | 0.00 | -8.99 | 2.43 |
| 2025-06-06 | FBRX | 0.00 | -8.99 | 2.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.37
Avg. EPS Est. Current Quarter
-1.18
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
Institutional Transactions
-8.99
Beta
2.85
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
7
Growth Score
21
Sentiment Score
71
Actual DrawDown %
99.2
Max Drawdown 5-Year %
Target Price
48.67
P/E
Forward P/E
PEG
P/S
P/B
1.94
P/Free Cash Flow
EPS
-13.81
Average EPS Est. Cur. Y
-4.65
EPS Next Y. (Est.)
-2.8
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.38
Return on Equity vs Sector %
-137.8
Return on Equity vs Industry %
-119.8
EPS 1 7Days Diff
-1.1
EPS 1 30Days Diff
-1.06
EBIT Estimation
Forte Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 14
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
stock quote shares FBRX – Forte Biosciences Inc Stock Price stock today
news today FBRX – Forte Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FBRX – Forte Biosciences Inc yahoo finance google finance
stock history FBRX – Forte Biosciences Inc invest stock market
stock prices FBRX premarket after hours
ticker FBRX fair value insiders trading